Replies to post #158325 on Biotech Values

[mcbio]

Companies with failure in their past do change behaviour if/when they get compelling data*. I was willing to take a risk with Gern and made prospective decisions on what to buy and what to sell when. I'm just sticking to the system I have, and it has nothing to do with O'Karma. I came, I saw, and I've adjusted accordingly.

Are you still holding on in belief that MF data, or perhaps AML/MDS in due time, will be positive? Just curious. I'm still holding but debating whether I will continue to do so or just take my loss and move on. If nothing else, risk has substantially increased with the failure of several indications as it puts a lot more pressure on the need for the MF data due by the end of the year now to be positive. While I still find it hard to believe that imetelstat only works in ET, I also don't like the fact that GERN has now likely become a boom-or-bust play on the MF data. (And even if MF data is positive, I tend to think the ceiling has been lowered as there no longer exists the potential for imetelstat to work broadly in heme onc indications, or solid tumors for that matter.)

[bladerunner1717]

Did Wedbush just put $165 price target on PCYC. (I can't find any confirmation of that.)


Bladerunner